[Cisplatin and derivatives with radiation therapy: for what clinical use?].
Since its discovery by Rosenberg in 1965, cisplatin and its derivatives have appeared as the most important chemotherapeutic agents, particularly for their radiosensitizing properties and their clinical use with radiation. In spite of numerous preclinical and clinical studies, optimal schedules of platin and radiotherapy combination have to be defined. The first part of this overview will describe biological mechanisms of interaction between radiation therapy and platinum derivatives. The second part will report the major clinical impact of their association.
Durdux
C
C
Service d'oncologie-radiothérapie, hôpital européen Georges-Pompidou, AP-HP, HEGP, 20 rue Leblanc, 75015 Paris, France. catherine.maulard-durdux@hop.egp.ap-hop-paris.fr
D000818:Animals; D001005:Anus Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D007941:Leukemia P388 / Q000188:drug therapy / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D015201:Meta-Analysis as Topic; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy
D009944:Organoplatinum Compounds; D011838:Radiation-Sensitizing Agents; D000077150:Oxaliplatin; D016190:Carboplatin; D002945:Cisplatin; D006918:Hydroxyurea